Valbiotis SA (ALVAL.PA)
EUR 1.0
(-0.38%)
EUR 1.0
(-0.38%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -6.95 Million EUR | 35.36% |
| 2022 | -11.13 Million EUR | -33.46% |
| 2021 | -7.46 Million EUR | -125.07% |
| 2020 | -2.37 Million EUR | 27.16% |
| 2019 | -4.22 Million EUR | -33.68% |
| 2018 | -4.53 Million EUR | -94.3% |
| 2017 | -2.33 Million EUR | -326.33% |
| 2016 | -882 Thousand EUR | 40.35% |
| 2015 | -908 Thousand EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -3.44 Million EUR | 0.0% |
| 2023 Q4 | -5.15 Million EUR | 0.0% |
| 2023 FY | - EUR | 35.36% |
| 2023 Q2 | -1.66 Million EUR | 0.0% |
| 2022 Q4 | -7.76 Million EUR | 0.0% |
| 2022 FY | - EUR | -33.46% |
| 2022 Q2 | -5.49 Million EUR | 0.0% |
| 2021 FY | - EUR | -125.07% |
| 2021 Q2 | -3.53 Million EUR | 0.0% |
| 2021 Q4 | -6.39 Million EUR | 0.0% |
| 2020 Q4 | -1.73 Million EUR | 0.0% |
| 2020 FY | - EUR | 27.16% |
| 2020 Q2 | -2.68 Million EUR | 0.0% |
| 2019 FY | - EUR | -33.68% |
| 2019 Q4 | -2.89 Million EUR | 0.0% |
| 2019 Q2 | -3.16 Million EUR | 0.0% |
| 2018 FY | - EUR | -94.3% |
| 2018 Q4 | -2.67 Million EUR | 0.0% |
| 2018 Q2 | -1.85 Million EUR | 0.0% |
| 2017 Q4 | -2 Million EUR | 0.0% |
| 2017 FY | - EUR | -326.33% |
| 2017 Q2 | -323 Thousand EUR | 0.0% |
| 2016 Q1 | -136.75 Thousand EUR | 0.0% |
| 2016 FY | - EUR | 40.35% |
| 2016 Q4 | -551 Thousand EUR | 0.0% |
| 2016 Q2 | -11 Thousand EUR | 91.96% |
| 2015 Q4 | -136.75 Thousand EUR | 0.0% |
| 2015 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.29 Million EUR | -111.398% |
| ABIVAX Société Anonyme | -133.2 Million EUR | 94.779% |
| Adocia SA | -22.73 Million EUR | 69.404% |
| Aelis Farma SA | -6.34 Million EUR | -9.579% |
| Biophytis S.A. | -13.8 Million EUR | 49.616% |
| Advicenne S.A. | -6.24 Million EUR | -11.387% |
| genOway Société anonyme | 6.35 Million EUR | 209.515% |
| IntegraGen SA | -52.5 Thousand EUR | -13146.862% |
| Medesis Pharma S.A. | -3.84 Million EUR | -80.89% |
| Neovacs S.A. | -8.44 Million EUR | 17.688% |
| NFL Biosciences SA | -4.04 Million EUR | -71.758% |
| Plant Advanced Technologies SA | 72.53 Thousand EUR | 9689.136% |
| Quantum Genomics Société Anonyme | -2.87 Million EUR | -142.041% |
| Sensorion SA | -22.31 Million EUR | 68.831% |
| Theranexus Société Anonyme | -7.38 Million EUR | 5.851% |
| TME Pharma N.V. | -5.07 Million EUR | -37.125% |
| TheraVet SA | -517.33 Thousand EUR | -1244.387% |
| Valerio Therapeutics Société anonyme | -18.91 Million EUR | 63.232% |
| DBV Technologies S.A. | -79.53 Million EUR | 91.255% |
| Genfit S.A. | -28.05 Million EUR | 75.206% |
| GeNeuro SA | -14.31 Million EUR | 51.424% |
| Innate Pharma S.A. | -7.57 Million EUR | 8.221% |
| Inventiva S.A. | -101.84 Million EUR | 93.171% |
| MaaT Pharma SA | -19.74 Million EUR | 64.767% |
| MedinCell S.A. | -20.04 Million EUR | 65.305% |
| Nanobiotix S.A. | -34.01 Million EUR | 79.556% |
| OSE Immunotherapeutics SA | -23.26 Million EUR | 70.107% |
| Poxel S.A. | -12.17 Million EUR | 42.894% |
| GenSight Biologics S.A. | -21.73 Million EUR | 67.994% |
| Transgene SA | -27.02 Million EUR | 74.264% |
| Valneva SE | -64.51 Million EUR | 89.22% |